Next-Generation Oral SERD Approved for Breast Cancer

Summary
(MedPage Today) -- The FDA approved the next-generation oral selective estrogen receptor degrader (SERD) giredestrant (Wilserdly) in combination with everolimus for previously treated estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated...
Description from Medpagetoday.
Who is covering this
-
Next-Generation Oral SERD Approved for Breast Cancer
(MedPage Today) -- The FDA approved the next-generation oral selective estrogen receptor degrader (SERD) giredestrant (Wilserdly) in combination with everolimus for previously treated estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated...






Comments
Comments need JavaScript.